m+Medelevator.RU
← Поиск публикаций
Cochlear implants international · 2022

Effect of adaptive beamforming and noise reduction algorithms on speech intelligibility and noise tolerance in bimodal cochlear implant users.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Michels Anne, Oukheira Yassine, Brendel Martina, Aschendorff Antje, Arndt Susan, Wesarg Thomas

Аннотация

OBJECTIVE: To evaluate the effect of a directional microphone (beamformer) and continuous noise reduction algorithms (CNRs) in bimodally aided cochlear implant (CI) users and to find the optimum hearing aid (HA) and CI settings of the beamformer and CNRs.

METHODS: Speech reception threshold (SRT) and acceptable noise level (ANL) were assessed in twelve adult CI users for unilateral CI, unilateral HA and bimodal listening. To assess the effect of the UltraZoom beamformer and the ClearVoice™ and NoiseBlock CNRs on SRT and ANL, speech was presented from the front in multi-source speech-shaped noise.

RESULTS: With unilateral CI, application of UltraZoom resulted in a significant improvement of the median SRT and ANL by 3.8 and 4.3 dB, respectively. For bimodal listening with UltraZoom, a significant improvement of 3.5 dB in median SRT was found. There was no significant effect of using the CNRs on speech intelligibility in noise or noise tolerance in either listening condition.

CONCLUSION: UltraZoom should be applied on the CI to improve speech intelligibility in face to face conversations with multi-source background noise. However, due to the heterogeneous data, no recommendations for the settings of UltraZoom on the HA or of ClearVoice/NoiseBlock on either device can be given.

TRIAL REGISTRATION: German Clinical Trials Register identifier: DRKS00010807.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты